Weiss Ratings Reiterates Sell (E+) Rating for Veru (NASDAQ:VERU)

Key Points

• Weiss Ratings has reiterated a "Sell (E+)" rating for Veru (NASDAQ:VERU), indicating ongoing concerns about the company's stock performance.
• Raymond James Financial has reduced its price target for Veru from $30.00 to $20.00 while maintaining an "outperform" rating, amidst mixed analyst ratings.
• Veru's stock has seen a price of $3.80, with a 12-month performance highlighting a low of $2.64 and a high of $14.20, reflecting significant volatility in its valuation.

Veru (NASDAQ:VERU - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities researchers at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

Separately, Raymond James Financial reduced their target price on Veru from $30.00 to $20.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 13th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $33.33.

Veru Price Performance

Shares of NASDAQ:VERU traded up $0.08 during trading on Friday, hitting $3.80. 110,127 shares of the stock were exchanged, compared to its average volume of 148,646. The company has a fifty day moving average price of $3.71 and a two-hundred day moving average price of $4.82. Veru has a 12-month low of $2.64 and a 12-month high of $14.20.

Veru (NASDAQ:VERU - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.05. As a group, equities analysts forecast that Veru will post -0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. increased its holdings in shares of Veru by 17.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 1,423,288 shares of the company's stock worth $698,000 after buying an additional 206,614 shares during the last quarter. Oppenheimer & Co. Inc. increased its holdings in Veru by 18.3% in the 1st quarter. Oppenheimer & Co. Inc. now owns 1,325,246 shares of the company's stock valued at $650,000 after purchasing an additional 204,660 shares in the last quarter. Choreo LLC increased its holdings in Veru by 67.4% in the 1st quarter. Choreo LLC now owns 669,277 shares of the company's stock valued at $328,000 after purchasing an additional 269,500 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Veru by 19.3% in the 1st quarter. Bank of New York Mellon Corp now owns 377,043 shares of the company's stock valued at $185,000 after purchasing an additional 61,002 shares in the last quarter. Finally, Weaver Consulting Group increased its holdings in Veru by 27.4% in the 1st quarter. Weaver Consulting Group now owns 88,838 shares of the company's stock valued at $44,000 after purchasing an additional 19,133 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.